J Pediatr Pharmacol Ther
January 2009
Objective: To evaluate the use of recombinant factor VIIa (rFVIIa) for the treatment of bleeding in nonhemophiliac children.
Methods: This was a retrospective chart review of all patients < 18 years of age who received rFVIIa over a 2 year period.
Results: Twenty-four pediatric patients received a total of 240 doses of rFVIIa for treatment of bleeding.